Replimune Group, Inc.REPL stock score: 41/100
$19.23 · -2.93% · Scored Nov 19, 2026
- Technical
- 62
- Fundamental
- 36
- News
- 53
The reading
Replimune Group (REPL) scores 41 out of 100, which reads weak, higher than 28% of Healthcare stocks and 25% of the 4,118 US stocks we score.
The composite weights fundamentals 80% and technicals 20%: fundamentals read 36, technicals 62.
Among the fundamentals, Quick Ratio at 100 and Current Ratio at 100 score highest, while Free Cash Flow Yield at 0 weighs the most against it.
On the daily chart, trend-following indicators average 61 and contrarian oscillators 45.
News sentiment is neutral at 53; it is shown, not counted in the composite.
Since Aug 22, 2026 the composite has ranged from 38 to 51, and it is down 8 points over the period.
About Replimune Group
Replimune (REPL) is a biotechnology company that develops oncolytic immunotherapies, which use a modified herpes simplex virus to infect and destroy tumor cells while prompting the immune system to attack cancer elsewhere in the body. Its first product, Tudriqev, also known as RP1 or vusolimogene oderparepvec, received accelerated approval from the U.S. Food and Drug Administration for use with Bristol Myers Squibb’s Opdivo in patients with advanced melanoma whose disease has progressed after anti-PD-1 immunotherapy. Continued approval depends on results from an ongoing confirmatory Phase three trial. Tudriqev is injected directly into tumors by physicians at cancer centers. Replimune is also developing other candidates from the same platform, including RP2, for additional solid tumors. The company earns revenue from sales of Tudriqev and funds its research largely through cash raised from investors.
In advanced melanoma, Replimune competes with Iovance Biotherapeutics’ cell therapy and with drugs and combinations from Bristol Myers Squibb, Merck and other large drugmakers, as well as Amgen’s Imlygic, another oncolytic virus therapy. Its edge rests on an approved product for patients with few remaining options and a platform that may apply to other tumors that are hard to treat. Investors who follow REPL stock tend to watch the commercial launch of Tudriqev, including the number of treating centers and quarterly sales. Results from the confirmatory trial are closely followed. Data from its other programs, cash runway, operating expenses and the need for additional funding are other factors.
What’s driving the score
The strongest and weakest of the scorers that count toward REPL’s composite. Each returns 0–100, higher is more bullish — including metrics where low is good, like P/E.
Fundamental
36Pulling it up
- Quick Ratio100
Quick ratio measures a company's ability to meet short-term obligations with liquid assets.
Current assets divided by current liabilities: the ability to pay short-term bills.
Price target score compares the current stock price to analyst consensus targets.
Holding it back
Free cash flow yield is free cash flow divided by market value: the cash a business generates for each dollar of its price.
Return on Equity (ROE) measures how efficiently a company generates profits from shareholder equity.
Return on Assets (ROA) shows how efficiently a company uses its assets to generate profit.
26 weighted scorers; 13 had no data today and are left out rather than counted as zero.
Technical · daily
61Pulling it up
- EMA 100100
Exponential Moving Average (100-period) provides a responsive long-term trend view.
- EMA 200100
Exponential Moving Average (200-period) is a crucial long-term trend indicator that reacts faster than SMA-200.
- SMA 100100
Simple Moving Average (100-period) provides a longer-term perspective on price trends.
Holding it back
Candlestick patterns recognize specific price formations that historically suggest continuation or reversal.
Parabolic SAR (Stop and Reverse) provides trailing stop levels that follow price trends.
Simple Moving Average (10-period) smooths price action over 10 periods.
62 weighted scorers; 3 had no data today and are left out rather than counted as zero.
News · shown, not counted
- Global News
- 53
Technical score by timeframe
| Chart | Score | Weight |
|---|---|---|
| Hourly | 36 | 1 |
| Daily | 61 | 3 |
| Weekly | 68 | 2 |
| Monthly | 72 | 2 |
Composite score, last 90 days
Show the daily numbers
| Date | Composite |
|---|---|
| Nov 19, 2026 | 41 |
| Nov 18, 2026 | 41 |
| Nov 17, 2026 | 41 |
| Nov 16, 2026 | 41 |
| Nov 15, 2026 | 42 |
| Nov 14, 2026 | 41 |
| Nov 13, 2026 | 41 |
| Nov 12, 2026 | 38 |
| Nov 11, 2026 | 48 |
| Nov 10, 2026 | 49 |
| Nov 8, 2026 | 48 |
| Nov 7, 2026 | 48 |
| Nov 6, 2026 | 49 |
| Nov 5, 2026 | 48 |
| Nov 4, 2026 | 49 |
| Nov 3, 2026 | 50 |
| Nov 2, 2026 | 50 |
| Nov 1, 2026 | 49 |
| Oct 31, 2026 | 49 |
| Oct 30, 2026 | 49 |
| Oct 29, 2026 | 50 |
| Oct 28, 2026 | 48 |
| Oct 27, 2026 | 47 |
| Oct 26, 2026 | 44 |
| Oct 25, 2026 | 40 |
| Oct 24, 2026 | 40 |
| Oct 23, 2026 | 40 |
| Oct 22, 2026 | 42 |
| Oct 21, 2026 | 41 |
| Oct 20, 2026 | 40 |
| Oct 19, 2026 | 39 |
| Oct 18, 2026 | 39 |
| Oct 17, 2026 | 39 |
| Oct 16, 2026 | 39 |
| Oct 15, 2026 | 41 |
| Oct 14, 2026 | 41 |
| Oct 13, 2026 | 43 |
| Oct 12, 2026 | 47 |
| Oct 11, 2026 | 47 |
| Oct 10, 2026 | 47 |
| Oct 9, 2026 | 48 |
| Oct 8, 2026 | 46 |
| Oct 7, 2026 | 48 |
| Oct 6, 2026 | 48 |
| Oct 5, 2026 | 46 |
| Oct 4, 2026 | 48 |
| Oct 3, 2026 | 48 |
| Oct 2, 2026 | 47 |
| Oct 1, 2026 | 48 |
| Sep 30, 2026 | 47 |
| Sep 29, 2026 | 46 |
| Sep 28, 2026 | 43 |
| Sep 27, 2026 | 43 |
| Sep 26, 2026 | 43 |
| Sep 25, 2026 | 43 |
| Sep 24, 2026 | 45 |
| Sep 23, 2026 | 47 |
| Sep 22, 2026 | 47 |
| Sep 21, 2026 | 45 |
| Sep 20, 2026 | 45 |
| Sep 19, 2026 | 45 |
| Sep 18, 2026 | 46 |
| Sep 17, 2026 | 45 |
| Sep 16, 2026 | 44 |
| Sep 15, 2026 | 44 |
| Sep 14, 2026 | 45 |
| Sep 13, 2026 | 44 |
| Sep 12, 2026 | 44 |
| Sep 11, 2026 | 44 |
| Sep 10, 2026 | 44 |
| Sep 9, 2026 | 45 |
| Sep 8, 2026 | 47 |
| Sep 7, 2026 | 47 |
| Sep 6, 2026 | 47 |
| Sep 5, 2026 | 47 |
| Sep 4, 2026 | 47 |
| Sep 3, 2026 | 51 |
| Sep 2, 2026 | 49 |
| Sep 1, 2026 | 49 |
| Aug 31, 2026 | 48 |
| Aug 30, 2026 | 49 |
| Aug 29, 2026 | 49 |
| Aug 28, 2026 | 48 |
| Aug 27, 2026 | 49 |
| Aug 26, 2026 | 49 |
| Aug 25, 2026 | 50 |
| Aug 24, 2026 | 49 |
| Aug 23, 2026 | 48 |
| Aug 22, 2026 | 49 |
Key facts
- Market cap
- $1.8B
- Sector
- Healthcare
- Industry
- Biotechnology
- Beta
- 0.93
- Risk grade (1–10)
- 8
- Next earnings
- Oct 28, 2026
Biotechnology peers
| Company | Market cap | Score |
|---|---|---|
| ZYME Zymeworks | $1.9B | 53 |
| MRVI Maravai LifeSciences | $1.9B | 43 |
| SEPN Septerna | $1.9B | 56 |
| MAZE Maze Therapeutics | $1.8B | 34 |
| STOK Stoke Therapeutics | $1.8B | 52 |
| RARE Ultragenyx Pharmaceutical | $1.8B | 47 |
Questions
What is REPL's stock rating today?
REPL scores 41/100 (Weak) as of Nov 19, 2026: technical 62, fundamental 36, and news sentiment 53, which is shown but not counted. Scores are recomputed every night.
What does Replimune Group do?
Replimune (REPL) is a biotechnology company that develops oncolytic immunotherapies, which use a modified herpes simplex virus to infect and destroy tumor cells while prompting the immune system to attack cancer elsewhere in the body. Its first product, Tudriqev, also known as RP1 or vusolimogene oderparepvec, received accelerated approval from the U.S.
Is REPL stock a buy?
The score is not a buy or sell recommendation. A 41 says the technical and fundamental signals we measure lean weak today, relative to every other stock scored the same way. Use the breakdown above to see why, and treat it as a starting point for your own research.
How is the REPL score calculated?
88 weighted scorers feed it today: 26 fundamental, scored against Healthcare ranges, and 62 technical on the daily chart, with 4 timeframes blended into the technical total. Every scorer returns 0–100; missing data is left out, never counted as zero.
Scores are information, not investment advice. Computed from Yahoo Finance, Finnhub and Alpha Vantage data; technical indicators via TA-Lib. Past scores do not predict future returns.
Embed this score
A badge for a blog post, newsletter or README. It updates every night and links back here. More badges
HTML
<a href="https://stocksscores.com/stocks/repl/"><img src="https://stocksscores.com/stocks/repl/badge.svg" alt="REPL stock score" height="20"></a>
Markdown
[](https://stocksscores.com/stocks/repl/)